|
Re: Re San fran
|
2
|
Resverlogix Corp.
|
Oct 19, 2020 01:34PM
|
|
Re: Recent findings point to BET protein and ACE2 inhibition as possible means to slow and reduce the impact of COVID-19....
|
3
|
Resverlogix Corp.
|
Mar 23, 2020 09:44AM
|
|
Re: Recent findings point to BET protein and ACE2 inhibition as possible means to slow and reduce the impact of COVID-19....
|
2
|
Resverlogix Corp.
|
Mar 23, 2020 09:54AM
|
|
Re: Reddit.
|
1
|
Resverlogix Corp.
|
Mar 04, 2021 01:12PM
|
|
Re: Repetitive musings on repetitive issues
|
|
Resverlogix Corp.
|
Feb 14, 2021 07:47AM
|
|
Re: Response & what I will attempt...
|
|
Zenith Epigenetics
|
Aug 17, 2020 02:22PM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
4
|
Resverlogix Corp.
|
Dec 22, 2020 08:13AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
4
|
Resverlogix Corp.
|
Dec 22, 2020 08:42AM
|
|
Re: Resverlogix Announces Participation at the ACC/WCC Virtual Meeting
|
2
|
Resverlogix Corp.
|
Mar 31, 2020 08:18AM
|
|
Re: Resverlogix Announces Presentations
|
2
|
Resverlogix Corp.
|
Oct 17, 2020 12:57PM
|
|
Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
2
|
Resverlogix Corp.
|
Mar 31, 2020 05:18PM
|
|
Re: RESVERLOGIX ANNOUNCES WARRANT EXERCISE INCENTIVE PROGRAM
|
2
|
Resverlogix Corp.
|
Nov 25, 2019 07:12PM
|
|
Re: RESVERLOGIX ANNOUNCES WARRANT EXERCISE INCENTIVE PROGRAM
|
5
|
Resverlogix Corp.
|
Nov 25, 2019 07:16PM
|
|
Re: RESVERLOGIX ANNOUNCES WARRANT EXERCISE INCENTIVE PROGRAM
|
3
|
Resverlogix Corp.
|
Nov 25, 2019 07:20PM
|
|
Re: RESVERLOGIX ANNOUNCES WARRANT EXERCISE INCENTIVE PROGRAM
|
3
|
Resverlogix Corp.
|
Nov 25, 2019 07:33PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
1
|
Resverlogix Corp.
|
Mar 24, 2020 12:53PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
5
|
Resverlogix Corp.
|
Mar 26, 2020 03:12PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
2
|
Resverlogix Corp.
|
Mar 26, 2020 03:45PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
3
|
Resverlogix Corp.
|
Mar 27, 2020 11:31AM
|
|
Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
4
|
Resverlogix Corp.
|
Dec 02, 2019 10:56AM
|
